Low-dose aspirin or other nonsteroidal anti-inflammatory drug use and prostate cancer risk: a nationwide study

Charlotte Skriver, Christian Dehlendorff, Michael Borre, Klaus Brasso, Henrik Toft Sørensen, Jesper Hallas, Signe Benzon Larsen, Anne Tjønneland, Søren Friis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

PURPOSE: Increasing evidence suggests that aspirin use may protect against prostate cancer. In a nationwide case-control study, using Danish high-quality registry data, we evaluated the association between the use of low-dose aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) and the risk of prostate cancer.

METHODS: We identified 35,600 patients (cases) with histologically verified prostate cancer during 2000-2012. Cases were matched to 177,992 population controls on age and residence by risk-set sampling. Aspirin and nonaspirin NSAID exposure was defined by type, estimated dose, duration, and consistency of use. We used conditional logistic regression to estimate odds ratios (ORs), with 95 % confidence intervals (CIs), for prostate cancer associated with low-dose aspirin (75-150 mg) or nonaspirin NSAID use, adjusted for potential confounders.

RESULTS: Use of low-dose aspirin was associated with an OR for prostate cancer of 0.94 (95 % CI 0.91-0.97). Slightly lower ORs were seen with increasing cumulative amount, duration, and consistency of low-dose aspirin use (continuous use, ≥5 years: OR 0.89; 95 % CI 0.82-0.97; ≥10 years: OR 0.86; 95 % CI 0.70-1.06). Nonaspirin NSAID use was associated with a slightly increased OR for prostate cancer (1.13; 95 % CI 1.10-1.15); however, this association was confined to localized disease and did not vary materially with amount, duration, or consistency of nonaspirin NSAID use.

CONCLUSIONS: Our study indicates that long-term, consistent low-dose aspirin use may provide modest protection against prostate cancer. The slightly increased risk of only localized prostate cancer with nonaspirin NSAID use suggests a noncausal explanation of the observed association.

OriginalsprogEngelsk
TidsskriftCancer Causes & Control
Vol/bind27
Udgave nummer9
Sider (fra-til)1067–1079
ISSN0957-5243
DOI
StatusUdgivet - 2016

Fingeraftryk

Prostatic Neoplasms
Odds Ratio
Pharmaceutical Preparations
Confidence Intervals
Population Control
Registries
Case-Control Studies
Logistic Models

Citer dette

Skriver, Charlotte ; Dehlendorff, Christian ; Borre, Michael ; Brasso, Klaus ; Sørensen, Henrik Toft ; Hallas, Jesper ; Larsen, Signe Benzon ; Tjønneland, Anne ; Friis, Søren. / Low-dose aspirin or other nonsteroidal anti-inflammatory drug use and prostate cancer risk : a nationwide study. I: Cancer Causes & Control. 2016 ; Bind 27, Nr. 9. s. 1067–1079.
@article{2b5905918cfd43fc911a9b9dadd52d93,
title = "Low-dose aspirin or other nonsteroidal anti-inflammatory drug use and prostate cancer risk: a nationwide study",
abstract = "PURPOSE: Increasing evidence suggests that aspirin use may protect against prostate cancer. In a nationwide case-control study, using Danish high-quality registry data, we evaluated the association between the use of low-dose aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) and the risk of prostate cancer.METHODS: We identified 35,600 patients (cases) with histologically verified prostate cancer during 2000-2012. Cases were matched to 177,992 population controls on age and residence by risk-set sampling. Aspirin and nonaspirin NSAID exposure was defined by type, estimated dose, duration, and consistency of use. We used conditional logistic regression to estimate odds ratios (ORs), with 95 {\%} confidence intervals (CIs), for prostate cancer associated with low-dose aspirin (75-150 mg) or nonaspirin NSAID use, adjusted for potential confounders.RESULTS: Use of low-dose aspirin was associated with an OR for prostate cancer of 0.94 (95 {\%} CI 0.91-0.97). Slightly lower ORs were seen with increasing cumulative amount, duration, and consistency of low-dose aspirin use (continuous use, ≥5 years: OR 0.89; 95 {\%} CI 0.82-0.97; ≥10 years: OR 0.86; 95 {\%} CI 0.70-1.06). Nonaspirin NSAID use was associated with a slightly increased OR for prostate cancer (1.13; 95 {\%} CI 1.10-1.15); however, this association was confined to localized disease and did not vary materially with amount, duration, or consistency of nonaspirin NSAID use.CONCLUSIONS: Our study indicates that long-term, consistent low-dose aspirin use may provide modest protection against prostate cancer. The slightly increased risk of only localized prostate cancer with nonaspirin NSAID use suggests a noncausal explanation of the observed association.",
keywords = "Journal Article",
author = "Charlotte Skriver and Christian Dehlendorff and Michael Borre and Klaus Brasso and S{\o}rensen, {Henrik Toft} and Jesper Hallas and Larsen, {Signe Benzon} and Anne Tj{\o}nneland and S{\o}ren Friis",
year = "2016",
doi = "10.1007/s10552-016-0785-7",
language = "English",
volume = "27",
pages = "1067–1079",
journal = "Cancer Causes & Control",
issn = "0957-5243",
publisher = "Springer",
number = "9",

}

Skriver, C, Dehlendorff, C, Borre, M, Brasso, K, Sørensen, HT, Hallas, J, Larsen, SB, Tjønneland, A & Friis, S 2016, 'Low-dose aspirin or other nonsteroidal anti-inflammatory drug use and prostate cancer risk: a nationwide study', Cancer Causes & Control, bind 27, nr. 9, s. 1067–1079. https://doi.org/10.1007/s10552-016-0785-7

Low-dose aspirin or other nonsteroidal anti-inflammatory drug use and prostate cancer risk : a nationwide study. / Skriver, Charlotte; Dehlendorff, Christian; Borre, Michael; Brasso, Klaus; Sørensen, Henrik Toft; Hallas, Jesper; Larsen, Signe Benzon; Tjønneland, Anne; Friis, Søren.

I: Cancer Causes & Control, Bind 27, Nr. 9, 2016, s. 1067–1079.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Low-dose aspirin or other nonsteroidal anti-inflammatory drug use and prostate cancer risk

T2 - a nationwide study

AU - Skriver, Charlotte

AU - Dehlendorff, Christian

AU - Borre, Michael

AU - Brasso, Klaus

AU - Sørensen, Henrik Toft

AU - Hallas, Jesper

AU - Larsen, Signe Benzon

AU - Tjønneland, Anne

AU - Friis, Søren

PY - 2016

Y1 - 2016

N2 - PURPOSE: Increasing evidence suggests that aspirin use may protect against prostate cancer. In a nationwide case-control study, using Danish high-quality registry data, we evaluated the association between the use of low-dose aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) and the risk of prostate cancer.METHODS: We identified 35,600 patients (cases) with histologically verified prostate cancer during 2000-2012. Cases were matched to 177,992 population controls on age and residence by risk-set sampling. Aspirin and nonaspirin NSAID exposure was defined by type, estimated dose, duration, and consistency of use. We used conditional logistic regression to estimate odds ratios (ORs), with 95 % confidence intervals (CIs), for prostate cancer associated with low-dose aspirin (75-150 mg) or nonaspirin NSAID use, adjusted for potential confounders.RESULTS: Use of low-dose aspirin was associated with an OR for prostate cancer of 0.94 (95 % CI 0.91-0.97). Slightly lower ORs were seen with increasing cumulative amount, duration, and consistency of low-dose aspirin use (continuous use, ≥5 years: OR 0.89; 95 % CI 0.82-0.97; ≥10 years: OR 0.86; 95 % CI 0.70-1.06). Nonaspirin NSAID use was associated with a slightly increased OR for prostate cancer (1.13; 95 % CI 1.10-1.15); however, this association was confined to localized disease and did not vary materially with amount, duration, or consistency of nonaspirin NSAID use.CONCLUSIONS: Our study indicates that long-term, consistent low-dose aspirin use may provide modest protection against prostate cancer. The slightly increased risk of only localized prostate cancer with nonaspirin NSAID use suggests a noncausal explanation of the observed association.

AB - PURPOSE: Increasing evidence suggests that aspirin use may protect against prostate cancer. In a nationwide case-control study, using Danish high-quality registry data, we evaluated the association between the use of low-dose aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) and the risk of prostate cancer.METHODS: We identified 35,600 patients (cases) with histologically verified prostate cancer during 2000-2012. Cases were matched to 177,992 population controls on age and residence by risk-set sampling. Aspirin and nonaspirin NSAID exposure was defined by type, estimated dose, duration, and consistency of use. We used conditional logistic regression to estimate odds ratios (ORs), with 95 % confidence intervals (CIs), for prostate cancer associated with low-dose aspirin (75-150 mg) or nonaspirin NSAID use, adjusted for potential confounders.RESULTS: Use of low-dose aspirin was associated with an OR for prostate cancer of 0.94 (95 % CI 0.91-0.97). Slightly lower ORs were seen with increasing cumulative amount, duration, and consistency of low-dose aspirin use (continuous use, ≥5 years: OR 0.89; 95 % CI 0.82-0.97; ≥10 years: OR 0.86; 95 % CI 0.70-1.06). Nonaspirin NSAID use was associated with a slightly increased OR for prostate cancer (1.13; 95 % CI 1.10-1.15); however, this association was confined to localized disease and did not vary materially with amount, duration, or consistency of nonaspirin NSAID use.CONCLUSIONS: Our study indicates that long-term, consistent low-dose aspirin use may provide modest protection against prostate cancer. The slightly increased risk of only localized prostate cancer with nonaspirin NSAID use suggests a noncausal explanation of the observed association.

KW - Journal Article

U2 - 10.1007/s10552-016-0785-7

DO - 10.1007/s10552-016-0785-7

M3 - Journal article

C2 - 27503490

VL - 27

SP - 1067

EP - 1079

JO - Cancer Causes & Control

JF - Cancer Causes & Control

SN - 0957-5243

IS - 9

ER -